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Summary We investigated the effect of the flavonoid quercetin (Q) on the proliferation of the ovarian cancer
cell line OVCA 433. Growth experiments demonstrated that Q exerted a reversible dose-dependent inhibition
of cell proliferation in the range of concentrations between 10 nm and 10 M. Two other flavonoids tested,
rutin and hesperidin, were ineffective in inhibiting cell growth. Cell cycle analysis showed that the growth
inhibitory effect of Q was due to a blocking effect in the GO/GI phase. Using a whole cell assay with (6,7-3H)
oestradiol (3H-E2) as tracer we demonstrated that OVCA 433 cells contain type II oestrogen binding sites
(type II EBS). Competition analysis showed that Q competed for 3H-E2 binding to type 11 EBS while both
rutin and hesperidin did not. Appreciable amounts of type 11 EBS were also detected in seven primary ovarian
tumours. Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a
binding interaction with type II EBS. This mechanism could also be active in vivo since primary ovarian
tumours contain type II EBS.
Flavonoids are a widely distributed class of natural sub-
stances with a variety of biological actions (Gabor, 1988).
Recently it has been reported that in the rat uterus and in the
MCF-7 human breast cancer cell line the flavonoid quercetin
(Q) inhibits cell growth and the uterotrophic response to
oestradiol (Markaverich et al., 1988). Although the mech-
anism of the antiproliferative activity of Q remains to be
fully clarified, there is evidence suggesting that the action of
this substance is probably mediated by its interaction with
the so-called type II oestrogen binding site (type II EBS)
(Markaverich et al., 1988). These sites originally described by
Clark et al. (1978) in rat uterus, while displaying the same
steroid and tissue specificity, are distinct from the 'true'
oestrogen receptor (ER). They are reported to be present in
higher concentrations than ER but to have a lower apparent
affinity dissociation constant (KD 10-20 nM) for E2 than ER
(KD 0.2-1 nM).
This possibility is supported by the demonstration that in
rat uterus type II EBS are occupied in vivo by a flavonoid-
like ligand with growth inhibitory activity (Markaverich et
al., 1983a,b). We report here that Q has an antiproliferative
effect against human ovarian cancer cells in culture and that
these cells express appreciable amounts of type II EBS.
Moreover, we demonstrate that type II EBS are also present
in primary ovarian tumours.
Materials and methods
Cell culture
OVCA 433 ovarian cancer cells were kindly provided by
Dr B. Littlefield (Department of Gynecology, Yale Univer-
sity, USA). Cells were grown in monolayer culture in
minimum essential medium (MEM) supplemented with 10%
fetal calf serum (FCS) and 200 units ml' penicillin. Cells
were trypsinised weekly and plated at a density of 8 x 104
cells ml'. They were incubated at 37°C under 5% CO2 95%
air in a high humidity atmosphere.
Growth experiments
Cells were plated in six-well flat bottom plates (Falcon 3046,
Becton Dickinson, Lincoln Park, NJ, USA) at a concentra-
tion of I x 105 cells ml-' in MEM supplemented as above.
After 24 h, the medium was replaced with fresh medium and
Q (3,3',4',5,7-pentahydroxyflavone), rutin (3-rhamnosylgluco-
side of Q) and hesperidin (7-rhamnosylglucoside of Hesperi-
tin) (3'-5-3-hydroxy-4-methoxy-flavanone) (Aldrich, Stein-
hein, FRG) were added from an absolute ethanol (Q) or
DMSO stock solution (rutin, hesperidin). Control cells were
treated with the same amount of vehicle alone. The final
ethanol and DMSO concentration never exceeded 1% (v/v)
and 0.5% (v/v), in either control or treated samples, respec-
tively.
Quadruplicate haemocytometer counts of triplicate culture
dishes were performed at the time indicated in the figures.
Cell cycle analysis
OVCA 433 cells were plated at a concentration of I x 105
cells ml-' in MEM supplemented as above. Twenty-four
hours after plating, medium was replaced with fresh medium
containing 1O0M Q or vehicle alone (ethanol). After 3 days,
cells were incubated for 30 min at 37°C in the same medium
with 10ftM bromodeoxyuridine (Sigma Deisenhofen, FRG).
Cells were detached with a cell scraper, centrifuged at 1,500 g
for 5min at 20°C and washed twice by resuspending in
phosphate buffered saline (PBS) pH 7.4 at 20°C. The cell
pellet was fixed by resuspending in 50% (v/v) absolute
ethanol in PBS containing 10mM EDTA. Cells were then
washed twice with 0.5% (v/v) Tween 20 in PBS and treated
with 3 N HCL solution for 30 min at room temperature for
DNA denaturation. After two washes with 0.5% (v/v) Tween
20 in PBS the reaction was stopped by resuspending cells
with 0.1 M sodium tetraborate pH 8.5. The cell pellet was
then resuspended in 100jil PBS containing 20fLl of anti-
bromodeoxy-uridine antibody (Becton Dickinson, Lab Impex
Ltd, Middlesex, UK) for 30 min at room temperature. The
cells were then washed twice with PBS and incubated for
30 min with 2.5 p1 per 106 cells FITC-conjugated goat-anti
mouse IgG in PBS. After washing twice with 0.5% (v/v)
Tween 20 in PBS the cell pellet was resuspended in PBS
containing 25 fg ml' propidium iodide (Sigma). Stained
cells were analysed by the Facscan cytometer (Becton Dick-
inson) and results calculated according to Khochbin et al.
(1988).
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Type II EBS analysis in 0VCA 433
Type II EBS were measured with a whole cell assay pre-
viously described (Ranelletti et al., 1988) with slight modifi-
cations. Cells were plated into Multiwell TM (Falcon 3047)
at a concentration of 5 x 104 cells ml-' in MEM supple-
mented as above. After 24 h, the medium was replaced with
fresh medium without serum containing increasing concentra-
tions (4-50 nM) of 3H-E2 (40 Ci mmol
' Amersham, UK)
alone or in the presence of a 100-fold molar excess of
diethylstilbestrol (DES) (SIGMA) at 4°C for 2.5 h. At the
end of the incubation period, cells were rapidly washed twice
with ice-cold MEM and then incubated in I M NaOH for
30 min at 50°C. Radioactivity was measured by a liquid
scintillation spectrometer (LS-7000, Beckman, Palo Alto, CA,
USA). Specific binding was calculated as the difference
between the binding in the absence (total binding) and in the
presence of DES (non-specific binding). Results were expres-
sed as the number of binding sites per cell. The conversion of
radioactivity to number of sites per cell was accomplished by
determining the amount of 3H-E2 bound for aliquots derived
from a known number of cells and by applying Avogadro's
number.
Type II EBS analysis in tumour specimens
Fresh tissue specimens from primary tumours were removed
in the operating room, frozen immediately on dry ice, and
stored at -80°C until assay. Tissues were finely minced and
homogenised in five volumes of ice-cold buffer consisting of
10 mM Tris, 1.5 mM EDTA, 5 mM NaN3 (TEN) by applying
three to four 10s bursts of an Ultra-Turrax homogeniser with
intermittent cooling. The crude homogenate was centrifuged
at 105,000 g for 30 min at 0°C and the resulting supernatant
was used for type II EBS analysis. Briefly, 250 jl of cytosol
were incubated at 30°C for 30 min with increasing concentra-
tions of 3H-E2 (4-50 nM) without or with a 300-fold molar
excess of DES. Bound and free steroids were separated by
hydroxylapatite method, as previously reported (Clark et al.,
1978). Specific binding was calculated as the difference be-
tween the binding in the absence (total binding) and in the
presence (non specific binding) of unlabelled DES. Protein
concentration was determined by the method of Bradford
(1976).
Oestrogen andprogesterone receptor analysis
Oestrogen (ER) and progesterone (PR) receptors were as-
sayed according to EORTC protocols (1980).
Results
Growth inhibitory effect on Q on OVCA 433 cells
Figure 1 shows the effects of different flavonoids on OVCA
433 cell proliferation. Q produced a dose-dependent inhibi-
tion of cell growth while, even at the highest concentration
tested (10 1M), rutin and hesperidin did not have any
significant effect. When the time-dependent effect of Q was
evaluated, it appeared that the antiproliferative action was
already evident 24 h after the addition of the substance
(Figure 2).
The inhibitory effect of Q was not due to a non-specific
cytotoxic action. In fact, cell viability which was more than
85% did not vary between control and treated cells, after the
3 day culture period. Furthermore, the inhibitory effect
appears to be reversible since after the removal of Q, treated
OVCA 433 cells regrew like untreated cells (Figure 3).
To study further the antiproliferative activity of Q, we
analysed the effect of this substance on the OVCA 433 cell
cycle. As shown in Table I, the cytometric flow analysis
revealed that Q produces an increase in the percentage of
cells in the GO/GI phase of the cycle with a relative decrease
of those in the S phase.
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Figure 1 Effect of various concentrations of flavonoids on
OVCA 433 cell proliferation. Cell counts were performed after 3
days of exposure to quercetin (0), rutin (0) and hesperidin (A).
Each value represents the mean s.d. of three different experi-
ments performed in triplicate.
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Figure 2 Time course of the antiproliferative effect of quercetin
(Q) on OVCA 433 cells. Cells were cultured without (0) or with
Q (0) at 1OIJM, for the time indicated. Results represent the
means ± s.d. of triplicate determinations from one of two similar
experiments.
TableI Effect ofquercetin on thedistribution ofOVCA 433 cells in the
different stages of the cell cycle
Treatmenta
None Q (10I1M)
GO/GI 68.15 2.job 78.24 2.54c
S 26.73 + 0.68 16.56 ± 0.49c
G2/M 5.1±0.13 5.1±0.21
'OVCA 433 cells were cultured for two days without or with Q at
10JAM; bResults areexpressed aspercentage ofcells in eachphase ofthe
cellcycle. Values represent themeans ± s.d. oftriplicatedeterminations
from one of three similar experiments; P< 0.01 compared with
untreated cells by Student's t test.944 G. SCAMBIA et al.
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Figure 3 Reversibility of the antiproliferative effect of quercetin
(Q) on OVCA 433 cells. Cells were cultured without (0) or with
10 iM Q (0) for 2 days or continuously (dotted line). Results
represent the means ± s.d. of triplicate determinations from one
of two similar experiments.
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Figure 4 a, Specific binding of 3H-E2 as a function of tracer
concentration in OVCA 433 cells. Specifically bound 3H-E2 was
measured as detailed in Materials and methods. b, Scatchard
analysis of data from a.
Table II Steroid specificity of type II EBS in OVCA 433
Competing steroids' % binding
None 100
17-$-oestradiol 37 ± 6
Diethylstilbestrol 32 ± 7
Progesterone 99 ± 12
5-a-dihydrotestosterone 100 + 13
Androstenedione 95 ± 10
Dexamethasone 90± 8
Quercetin 25 ± 8
Rutin 88 15
Hesperidin 95± 8
Values are the mean ± s.d. (n = 5 different experiments). 'All
competing steroids were at a 100-fold molar excess relative to 3H-E2
(40nM).
Type II EBS in 0VCA 433 cells
Since Q has been reported to exert its inhibitory effect
through an interaction with type II EBS (Markaverich et al.,
1988) we looked for the presence of these binding sites in
OVCA 433 cells. As shown in Figure 4a, in these cells the
saturation analysis carried out by a whole cell assay at 4°C
for 2.5 h resulted in a sigmoid curve with saturation occurr-
ing between 40 and 50 nM 3H-E2. As predicted from the
biphasic nature of the saturation curve, Scatchard analysis of
the binding values yielded a concave plot (Figure 4b) similar
to that previously observed in other type II expressing
systems (Ranelletti et al., 1988). Since an accurate estimate of
both the KD and the number of EBS cannot be made from a
curvilinear Scatchard plot, these parameters were obtained
from the saturation curve (Clark et al., 1978; Ranelletti et al.,
1988).
For the experiment shown in Figure 4 the number of type
II EBS calculated from the saturation curve at maximum
binding is about 290,000 sites per cell. The KD determined
from the 3H-E2 concentration required for half saturation is
about 18 nM. In six similar experiments the number of sites
per cell and the KD values were 320,900 ± 85,000 s.d. and
16 nM± 3 s.d., respectively. Specificity experiments demon-
strated that among different steroids tested only oestrogenic
compounds inhibited the binding of 3H-E2 to type II EBS
(Table II). The data in the same table show that Q is able to
compete with 3H-E2 for type II EBS binding with a potency
similar to that of DES. Furthermore, 3-rhamnosyl-glucoside
of Q (rutin) and hesperetin-7-rutinoside (hesperidin) do not
compete at all.
Type II EBS in primary ovarian cancer
Type II EBS are expressed in appreciable amounts in pri-
mary ovarian tumours too. The morphology of both 3H-E2
binding curve to type II EBS and the Scatchard plot of
binding data closely resemble those observed for OVCA 433
cells (data not shown). As shown in Table III all tumour
specimens tested contained type II EBS, with values ranging
from 2665 fmol mg-' of protein to 5,200 fmol mg-' protein
and KD values from 13 to 18 nM. In the presence of 10mM
dithiothreitol (DTT) the binding of 3H-E2 to type II EBS
was reduced to approximately 30% of the control (without
DTT) value (data not shown). This sensitivity to reducing
agents is similar to that previously observed for type II EBS
in rat uterus (Markaverich et al., 1981).
In all cases Q displaced 3H-E2 from the type II EBS with a
potency similar to that of DES, since the percentage of
displacement are between 80% and 90% of the total bound.
Four and three cases expressed ER and PR respectively
(Table III). However, although the number of specimens
tested are very small, no correlation was found between type
II EBS levels and ER and PR concentration. Furthermore, Q
did not compete for 3H-E2 binding to ER (data not shown).
Table III Type II EBS ER and PR in primary ovarian tumours
Patient Histology Type II EBS (KD, nM) ER (KD, nM) PR (KD, nM)
A.T. Serous 4875a (13)b 55 (0.6)C 120 (0.8)
V.P. Serous 4943 (15) n.d. n.d.
M.G.R. Serous 5200 (14) 12 (1) 18 (0.4)
O.M. Serous 3569 (18) n.d. n.d.
P.M. Serous 2665 (16) 26 (0.4) n.d.
L.M. Serous 4191 (15) n.d. n.d.
G.C. Serous 3492 (14) 66 (0.6) 44 (0.7)
n.d. = not detectable. afmol mg-' ofprotein calculated from the saturation curve at maximum binding.
bCalculated as the 3H-E2 concentration required for half-saturation. cfmolmg-' of protein and (KD)
calculated from the Scatchard's analysis of binding data.
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Discussion
Our data indicate that the flavonoid Q inhibits the growth of
human ovarian cancer cells. This finding is in agreement with
previous studies showing that Q has an antiproliferative
action against human cancer cells in vitro (Markaverich et al.,
1988; Yoshida et al., 1990). The observation that a dietary
supplement of Q inhibits the development of 7,12-dimethyl-
benzanthracene and N-nitrosomethylurea induced rat mam-
mary cancer (Verma et al., 1988) strongly support the pos-
sibility that Q could also be active in vivo. In addition Q and
certain related flavonoids may be inhibitors of experimental
skin carcinogenesis (Nakadate et al., 1984; Nishino et al.,
1984; Chang et al., 1985).
Although the mechanism of the antiproliferative activity of
Q remains to be clarified, our data suggest that as in human
breast cancer (Markaverich et al., 1988) and leukaemic cells
(Larocca et al., 1990), this flavonoid may regulate cell growth
through a binding interaction with type II EBS. This hypo-
thesis is supported by the following observations: (a) among
the flavonoids tested only Q inhibits cell growth while both
rutin and hesperidin, which do not bind to type II EBS are
ineffective; (b) the cell growth inhibitory effect of Q is dose-
dependent and readily reversible upon removal of the sub-
stance indicating that Q does not act as a non-specific toxin
randomly impairing the cellular metabolic machinery; (c)
although bioflavonoids affect a variety of enzymes (Lang &
Racker, 1974; Monaham et al., 1975; Kuriki & Racker, 1976;
Bustamante & Pedersen, 1977; Graziani, 1977; Shosham &
MacLennam, 1981; Graziani et al., 1983; Nishino et al.,
1983) the concentrations eliciting these effects are in the
range of 50-1I00 M. Conversely, Q both interacts with type
II EBS and becomes effective as cell growth inhibitor at
concentrations starting from 0.01 SAM.
Cytofluorimetric results indicate that the growth inhibitory
effect of Q depends on a blocking action of cell transition
from the GO/GI to the S phase of the cell cycle. This
observation is in agreement with previous studies on human
gastric cancer (Yoshida et al., 1990) and IM 9 lymphoblas-
toid cells (unpublished observation).
Interestingly, primary ovarian tumours express appreciable
amounts of type II EBS. Since type II EBS may be related to
the control of cell growth it can be hypothesised that these
binding sites may represent a biochemical parameter with
possible prognostic significance.
The growth inhibitory properties of Q, together with the
presence of type II EBS in primary ovarian cancer, suggest
that this substance could be of some therapeutic potential.
Interestingly, a plasma concentration of 12flM Q, which is
similar to that effective in vitro in inhibiting ovarian cancer
cell growth, was achieved following an intravenous injection
of 100 mg without any apparent side effect (Gugler et al.,
1975). In addition to its own antiproliferative activity, it is
worth noting that Q is able to enhance the antiproliferative
effect of cis-diamminedichloroplatinum and nitrogen mustard
in experimental tumour models (Hoffman et al., 1988) and in
the human leukaemia cell line K 562 (Hoffman et al., 1989).
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